Trial Condition(s):
Bronchiectasis
Treatment Patterns and Economic Burden of NCFB
Bayer Identifier:
18449
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
This observational database study used healthcare claims to understand costs and treatment pattern patients with non-cystic fibrosis bronchiectasis (NCFB) in the USA. Additionally, it looked at treatment patterns in this patient population to better understand how physicians respond in terms of treatment choices to an exacerbation.
Inclusion Criteria
- Adult NCFB patients with one claim for exacerbation during the enrollment period
Exclusion Criteria
- Patients with one primary or two secondary claims for COPD during the study period - Patients with any claims for cystic fibrosis or congential brochiectasis during the study period
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | Status | |
|---|---|---|
Locations Investigative Site Many locations, United States | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
Treatment Patterns and Healthcare Resource Utilization in Non Cystic Fibrosis Bronchiectasis (NCFB) Patients with Exacerbations
Trial Type:
Observational
Intervention Type:
N/A
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Cost and healthcare resource utilizationCosts and healthcare resource utilization in patients with NCFB who have experienced at least one exacerbation due to NCFB both in patients with an exacerbation that lead to hospitalization and an exacerbation that did not lead to a hospitalizationTimeframe: Up to 4 years
- Treatment pattern of NCFB patientsTreatment patterns of patients with NCFB who have experienced at least one exacerbation due to NCFB both in patients with an exacerbation that lead to hospitalization and an exacerbation that did not lead to a hospitalizationTimeframe: Up to 4 years
Secondary Outcome
- ComorbiditiesCommon comorbidities and coexisting disease in patients with NCFBTimeframe: Up to 4 years
- Healthcare resource utilization after different numbers of exacerbationsDifferences in healthcare resource utilization in patients with 1, 2, or 3 average annual exacerbationsTimeframe: Up to 4 years
Additional Information
Copyright © Bayer
Powered by
